Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3
J. Hall, Z. Zhang, D. Wang, S. Bhattacharya, M. Alcantara, Y. Liang, P. Swiderski, S. Forman, L. Kwak, N. Vaidehi, M. Kortylewski
This paper develops a PROTAC-based strategy to selectively degrade activated STAT3 in specific cell types, showing efficacy in reducing STAT3 levels and tumor growth in lymphoma models.
bioRxiv · Aug 1, 2023Cancer Biology